# Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

> **NCT06581848** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 150 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab

## Key facts

- **NCT ID:** NCT06581848
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2030-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581848, "Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06581848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*